Józsa Liza, Nemes Dániel, Pető Ágota, Kósa Dóra, Révész Réka, Bácskay Ildikó, Haimhoffer Ádám, Vasvári Gábor
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
Institute of Healthcare Industry, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.
Pharmaceutics. 2023 Apr 4;15(4):1146. doi: 10.3390/pharmaceutics15041146.
Bioavailability assessment in the development phase of a drug product is vital to reveal the disadvantageous properties of the substance and the possible technological interventions. However, in vivo pharmacokinetic studies provide strong evidence for drug approval applications. Human and animal studies must be designed on the basis of preliminary biorelevant experiments in vitro and ex vivo. In this article, the authors have reviewed the recent methods and techniques from the last decade that are in use for assessing the bioavailability of drug molecules and the effects of technological modifications and drug delivery systems. Four main administration routes were selected: oral, transdermal, ocular, and nasal or inhalation. Three levels of methodologies were screened for each category: in vitro techniques with artificial membranes; cell culture, including monocultures and co-cultures; and finally, experiments where tissue or organ samples were used. Reproducibility, predictability, and level of acceptance by the regulatory organizations are summarized for the readers.
在药品研发阶段进行生物利用度评估对于揭示药物物质的不利特性以及可能的技术干预措施至关重要。然而,体内药代动力学研究为药物批准申请提供了有力证据。人体和动物研究必须基于体外和离体的初步生物相关性实验来设计。在本文中,作者回顾了过去十年中用于评估药物分子生物利用度以及技术改进和药物递送系统效果的最新方法和技术。选择了四种主要给药途径:口服、透皮、眼部以及鼻腔或吸入。对每个类别筛选了三个层次的方法:使用人工膜的体外技术;细胞培养,包括单培养和共培养;最后是使用组织或器官样本的实验。为读者总结了监管机构对这些方法的可重复性、可预测性和接受程度。